Fig. 5

In vivo, the improved bioavailability of Lf-GL extended survival rate without systemic toxicity in orthotopic GBM mice model. a Pharmacokinetic study of GL and Lf-GL administered at a GL equivalent concentration of 50 mg kg.⁻¹ investigated for 1440 min. Data are expressed as mean ± S.E.M (n = 8). b Fluorescence tracer images of GL and Lf-GL 10 min after intravenous injection in all organs. White dashed line indicates the detected fluorescence signal in the brain. c Quantification of fluorescence intensity at each time point in the brain of mice treated with GL or Lf-GL intravenously. Data are expressed as mean ± S.E.M (n = 4). **P < 0.01 and ***P < 0.001 versus GL at each time point. N.D: non-detectable. d GL concentration detected in brain homogenate 10 min after drug injection. Data are expressed as mean ± S.E.M (n = 4). e Schematic illustration of treatment plan. f Survival rate of PBS-vehicle- (Control), Lf-, GL-, and Lf-GL- treated group for 28 days. Data are expressed as mean ± S.E.M (n = 8). g Body weight transformation of PBS-vehicle- (Control), Lf-, GL-, and Lf-GL- treated group for 28 days. Data are expressed as mean ± S.E.M (n = 8). h Spleen weight (mg) / body weight of PBS-vehicle- (Control), Lf-, GL-, and Lf-GL- treated group after 28 days of treatment. Data are expressed as mean ± S.E.M (n = 5)